Aktieanalys

Ascelia Pharma: The lead SPARKLE studies provide the first monthly progress update - Redeye

{newsItem.title}

Redeye Publicerad: 02 Jan 2023 08:05

Ascelia announced that 65 patients has now completed the SPARKLE study. This suggests that Ascelia is on track to achieved 80 patients by March or even late February.

Länk till analysen i sin helhet: https://www.redeye.se/research/870017/ascelia-pharma-the-lead-sparkle-studies-provide-the-first-monthly-progress-update?utm_source=finwire&utm_medium=RSS

Nyheter om Ascelia Pharma

Läses av andra just nu

Om aktien Ascelia Pharma

Senaste nytt